> top > docs > PMC:7696151 > spans > 66337-71299 > annotations

PMC:7696151 / 66337-71299 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1929 7-26 Disease denotes Autoimmune Diseases MESH:D001327
1966 1674-1703 Gene denotes E selectin and thrombomodulin Gene:6401
1967 669-677 Species denotes patients Tax:9606
1968 842-850 Species denotes patients Tax:9606
1969 1289-1297 Species denotes patients Tax:9606
1970 1814-1822 Species denotes patients Tax:9606
1971 2349-2357 Species denotes patients Tax:9606
1972 2600-2608 Species denotes patients Tax:9606
1973 2975-2983 Species denotes patients Tax:9606
1974 3233-3241 Species denotes patients Tax:9606
1975 27-30 Chemical denotes HCQ MESH:D006886
1976 341-351 Chemical denotes coadjutant
1977 506-509 Chemical denotes HCQ MESH:D006886
1978 511-525 Chemical denotes sulphasalazine MESH:D012460
1979 1382-1396 Chemical denotes sulphasalazine MESH:D012460
1980 1436-1439 Chemical denotes HCQ MESH:D006886
1981 1894-1897 Chemical denotes MXT MESH:D008727
1982 1910-1924 Chemical denotes sulphasalazine MESH:D012460
1983 1941-1944 Chemical denotes HCQ MESH:D006886
1984 2005-2023 Chemical denotes methylprednisolone MESH:D008775
1985 2036-2049 Chemical denotes triamcinolone MESH:D014221
1986 2407-2410 Chemical denotes HCQ MESH:D006886
1987 2463-2466 Chemical denotes HCQ MESH:D006886
1988 2716-2723 Chemical denotes 18F-FDG MESH:D019788
1989 2805-2819 Chemical denotes sulphasalazine MESH:D012460
1990 2836-2839 Chemical denotes HCQ MESH:D006886
1991 2926-2933 Chemical denotes 18F-FDG MESH:D019788
1992 3017-3020 Chemical denotes HCQ MESH:D006886
1993 3310-3320 Chemical denotes infliximab MESH:D000069285
1994 217-237 Disease denotes rheumatoid arthritis MESH:D001172
1995 363-383 Disease denotes rheumatoid arthritis MESH:D001172
1996 618-638 Disease denotes rheumatoid arthritis MESH:D001172
1997 1320-1340 Disease denotes rheumatoid arthritis MESH:D001172
1998 1575-1593 Disease denotes endothelial injury MESH:D014947
1999 1631-1649 Disease denotes endothelial injury MESH:D014947
2000 2621-2641 Disease denotes rheumatoid arthritis MESH:D001172
2001 3247-3276 Disease denotes juvenile idiopathic arthritis MESH:D001171
2028 3937-3942 Gene denotes IFN-α Gene:111654
2029 3524-3532 Species denotes patients Tax:9606
2030 3684-3690 Species denotes murine Tax:10090
2031 4389-4397 Species denotes patients Tax:9606
2032 4479-4487 Species denotes patients Tax:9606
2033 4557-4565 Species denotes patients Tax:9606
2034 4678-4686 Species denotes patients Tax:9606
2035 3534-3537 Chemical denotes HCQ MESH:D006886
2036 3634-3637 Chemical denotes HCQ MESH:D006886
2037 3718-3721 Chemical denotes HCQ MESH:D006886
2038 4332-4339 Chemical denotes aspirin MESH:D001241
2039 4341-4344 Chemical denotes HCQ MESH:D006886
2040 4584-4591 Chemical denotes aspirin MESH:D001241
2041 4599-4602 Chemical denotes HCQ MESH:D006886
2042 3503-3523 Disease denotes rheumatoid arthritis MESH:D001172
2043 3554-3573 Disease denotes lupus erythematosus MESH:D008180
2044 3583-3601 Disease denotes autoimmune disease MESH:D001327
2045 3613-3632 Disease denotes lupus erythematosus MESH:D008180
2046 3700-3705 Disease denotes lupus MESH:D008180
2047 3974-3979 Disease denotes lupus MESH:D008180
2048 4131-4136 Disease denotes lupus MESH:D008180
2049 4403-4408 Disease denotes lupus MESH:D008180
2050 4428-4438 Disease denotes thrombotic MESH:D013927
2051 4506-4534 Disease denotes cardiovascular complications MESH:D002318
2052 4649-4656 Disease denotes thrombo MESH:D054556
2053 4692-4697 Disease denotes lupus MESH:D008180
2058 4951-4955 Species denotes mice Tax:10090
2059 4748-4751 Chemical denotes HCQ MESH:D006886
2060 4839-4853 Chemical denotes cyclosporine A MESH:D016572
2061 4792-4817 Disease denotes graft-versus-host disease MESH:D006086

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T122 7-26 Phenotype denotes Autoimmune Diseases http://purl.obolibrary.org/obo/HP_0002960
T123 217-237 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T124 363-383 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T125 618-638 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T126 1320-1340 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T127 2621-2641 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T128 3247-3276 Phenotype denotes juvenile idiopathic arthritis http://purl.obolibrary.org/obo/HP_0005681
T129 3503-3523 Phenotype denotes rheumatoid arthritis http://purl.obolibrary.org/obo/HP_0001370
T130 3583-3601 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T425 0-6 Sentence denotes 2.4.1.
T426 7-26 Sentence denotes Autoimmune Diseases
T427 27-244 Sentence denotes HCQ belongs to the group of the disease-modifying antirheumatic drug (DMARD), which comprises drugs that are not chemically relted, sharing the same efficacy in dampening the progression of rheumatoid arthritis [122].
T428 245-390 Sentence denotes It often occurs also that glucocorticoids or natural antioxidant substances are included in the coadjutant therapy of rheumatoid arthritis [123].
T429 391-653 Sentence denotes A multicenter, randomized clinical trial analyzed the tolerability and the efficacy of combined therapy, including HCQ, sulphasalazine, MXT, and PRD with respect to the use of a single antirheumatic drug in the caring of early rheumatoid arthritis for two years.
T430 654-759 Sentence denotes A total of 195 patients were equally divided into two groups to follow the assigned therapeutic protocol.
T431 760-988 Sentence denotes The primary aim of clinical remission was achieved after one year by 24 of the 97 patients under combinatory therapy, while only by 11 of 98 single-drug therapy users, but this trend was further confirmed during the second year.
T432 989-1149 Sentence denotes After one year, 75% of subjects under combinatory therapy and 60% of those under single-therapy reached clinical improvement, intended as 50% clinical response.
T433 1150-1264 Sentence denotes In terms of tolerability, the cotreatment resulted not to be more dangerous with respect to the single drug [123].
T434 1265-1468 Sentence denotes In a prospective trial, patients with the diagnosis of rheumatoid arthritis were scheduled to receive cotreatment of sulphasalazine (1–3 g/day), MXT (7.5–15 mg/week), and HCQ (200 mg/day) for six months.
T435 1469-1594 Sentence denotes Significant improvements in clinical parameters revealed the efficacy of the cotreatment in counteracting endothelial injury.
T436 1595-1764 Sentence denotes Indeed, the blood concentrations of endothelial injury markers, mainly soluble E selectin and thrombomodulin, experienced a significant drop after the cotreatment [124].
T437 1765-2156 Sentence denotes Likewise, a single-blinded clinical trial on 281 patients confirmed the better therapeutic efficiency of cotreatment (25 mg/week MXT, 2 g/day of sulphasalazine, and 400 mg/day HCQ p.o. plus intramuscular injection (i.m.) doses of 120 mg of methylprednisolone or 80 mg of triamcinolone) with respect to single therapy after three months, without significant differences in side effects [125].
T438 2157-2516 Sentence denotes Proofs of the better antirheumatic potential of the combination of drugs with respect to single therapy derived from an observational study that evaluated the higher improvement of quality of patients’ life after one year of coadministration of MXT, HCQ, and corticosteroids with respect to single MXT, or HCQ, or their combination with corticosteroids [126].
T439 2517-2735 Sentence denotes Great insights in disease remission were provided by a clinical trial involving 17 patients with active rheumatoid arthritis where the chronic inflammatory status of joints was evaluated through the 18F-FDG PET method.
T440 2736-3007 Sentence denotes It was found that cotreatment with 7.5–15 mg/week of MXT, 2 g/day of sulphasalazine, 5 mg/kg/day of HCQ and a low dose of oral PRD (under 10 mg/day) is associated with a reduction of 30% in 18F-FDG uptake measures on PET imaging in 81% of patients after four weeks [127].
T441 3008-3114 Sentence denotes Although HCQ is effective and well-tolerated, other therapeutic alternatives have emerged in recent years.
T442 3115-3172 Sentence denotes Among them, monoclonal antibodies are the most promising.
T443 3173-3487 Sentence denotes In a multicenter open-label clinical trial, performed on 60 patients with juvenile idiopathic arthritis for 54 weeks, the combination of infliximab monoclonal antibodies with a conventional antirheumatic drug provided the better response in terms of disease inactivation with respect to DMARD administration [128].
T444 3488-3602 Sentence denotes In addition to rheumatoid arthritis patients, HCQ is also used in lupus erythematosus, another autoimmune disease.
T445 3603-3653 Sentence denotes Regarding lupus erythematosus, HCQ is widely used.
T446 3654-3993 Sentence denotes In vivo studies on a NZB/W F1 murine model of lupus showed that HCQ in combination with PRD (2.5 mg/kg/day and 1 mg/kg/day p.o.) decreased autoantibody production, as well as being able to inhibit toll-like receptor activation, resulting in the down-regulation of type I interferon (IFN-α) which is deeply implicated in lupus pathogenesis.
T447 3994-4302 Sentence denotes The efficacy of treatment is due to the ability of drugs to alter the expression of urinary and immune cell micro RNA that contribute to lupus progression by post-transcriptional modulation of genes involved in the immune response, pro-inflammatory cytokines production and toll-like receptor pathways [129].
T448 4303-4409 Sentence denotes In association with low-dose aspirin, HCQ is also indicated for thromboprophylaxis in patients with lupus.
T449 4410-4704 Sentence denotes The occurrence of thrombotic events was recorded for 13 years in 189 patients, showing that the cardiovascular complications were more frequent in patients treated only with aspirin, while HCQ (up to 600 mg) was associated with a stronger thrombo-protective effect in patients with lupus [130].
T450 4705-4854 Sentence denotes Thanks to its immunomodulatory properties, HCQ (20 mg/kg) was revealed to be useful in graft-versus-host disease, in combination with cyclosporine A.
T451 4855-4962 Sentence denotes They synergistically suppressed T cell response, allowing the reduction of the dose of drugs in mice [131].